Introduction
Malignant pleural mesothelioma (MPM) is an extremely aggressive tumor, which has been shown to be resistant to all conventional therapeutic regimens. A surgical resection is possible in only a minority of patients, and fewer than 15% of these patients live beyond 5 years (Sugarbaker et al., 1996; Boutin et al., 1998; Rusch and Venkatraman, 1999) . For those who are not treated with a curative resection, the median survival has been reported to be 6 months (Ruffie, 1991; De Pangher Manzini et al., 1993) . As a result, chemotherapy is still the mainstay of disease therapy. Various drugs including doxorubicin, cyclophosphamide, cisplatin (CDDP), carboplatin, gemcitabine (GEM) , and pemetrexed have been tested in different combinations (Samson et al., 1987; Chahinian et al., 1993; White et al., 2000; Kindler et al., 2001; Hughes et al., 2002) . However, the limited combinations of these agents have marginally provided some clinical benefit because of multidrug resistance. Moreover, none of the molecular targeting agents have shown any of their clinical benefit in the patients with MPM (Moore et al., 2007; Jackman et al., 2008) . Therefore, it is hoped that a better understanding of the mechanism of the multidrug resistance in MPM may provide the rationale for the development of new therapeutic strategies.
Drug resistance arises in numerous ways, such as through a decreased access to or uptake of drugs, the activation of repair and detoxification mechanisms, and an increased drug efflux. Among these numerous mechanisms, resistance against anti-cancer agents has been recently reported upon cell adhesion to the extracellular matrix (ECM) (Damiano et al., 1999; Elliott and Sethi, 2002; Hazlehurst et al., 2003) , thus suggesting that tumor-microenvironment interaction regulates the sensitivity of anti-cancer agents. For instance, it has been reported that small cell lung cancer cells, myeloma cells, glioma cells and colon cancer cells were protected from apoptosis induced by various anticancer agents when the cells were plated on ECM (Damiano et al., 1999; Sethi et al., 1999; Uhm et al., 1999; Kouniavsky et al., 2002) . MPM cells are surrounded by pleural effusion, which contains a variety of ECM including hyaluronate (HA) and osteopontin (OPN) (Thylen et al., 1997; Pass et al., 2005; Grigoriu et al., 2007) . The ability to grow in pleural fluid suggests that the MPM cells are capable of surviving and proliferating against apoptosis under the influence of this particular microenvironment. These findings indicate that the biological function of MPM appears to be strictly regulated by the interaction with ECM.
OPN, a secreted noncollagenous, phosphoprotein, functions as both an ECM component and cytokine through the binding to its receptors; integrin and CD44 (Denhardt et al., 2001) . OPN has been associated with cancer progression, metastasis and apoptosis (Rangaswami et al., 2006) . Several studies have revealed elevated levels of OPN in serum and pleural effusion to be observed in patients with MPM (Pass et al., 2005; Grigoriu et al., 2007) , thus suggesting the involvement of OPN in the pathogenesis of MPM. In fact, OPN was recently demonstrated to mediate MPM cell proliferation and migration (Ohashi et al., 2009) . OPN has also been reported to be involved in resistance to chemotherapy of mouse breast cancer cells by inhibiting apoptosis (Graessmann et al., 2007) . However, the role of OPN especially in multidrug resistance in MPM has not yet been clarified.
HA is a linear glycosaminoglycan, which is ubiquitously distributed in the ECM, and interacts with cell surface receptors including CD44 (Toole, 2004) . HA facilitates cell adhesion, cell motility, cellular proliferation and tumor progression (Lokeshwar et al., 1997 ). An increased HA production was found to upregulate drug resistance in cancer cells (Misra et al., 2003) . It is therefore possible that the effect of CD44 binding to HA on cell-survival signaling might alter drug resistance. In fact, HA-CD44 interaction was recently revealed to have a pivotal role in the chemoresistance in non-small cell lung cancer cells (Ohashi et al., 2007) . Very interestingly, recent studies have strongly supported the notion that the OPN could modulate the CD44 isoform expression, which closely regulates HA binding. For instance, Khan et al. (2005) reported that OPN modulates the specific CD44 isoform expression to facilitate breast cancer cell migration. Moreover, an overexpression of endogenous OPN results in increased hyaruronan synthase 2 activities, thus leading to an increased HA production and an enhanced anchorageindependent growth (Cook et al., 2006) .
Based on these findings, we hypothesized that OPN could regulate chemosensitivity through the alteration of CD44 binding to HA. We also discuss the potential mechanisms of the multidrug resistance in MPM.
Results
Generation of stable transfectant that secretes OPN BMGNeo-OPN and BMGNeo were transfected into the ACC-MESO-1 cells and we thus obtained two stable OPN-overexpressing clones (ACC-MESO-1/OPN#7 and ACC-MESO-1/OPN#8) and two control clones (ACC-MESO-1/Neo#1 and ACC-MESO-1/Neo#2). To verify the secretion of OPN protein from the transfectant, we conducted the ELISA for OPN. As shown in Figure 1a , ELISA demonstrated the ACC-MESO-1/ OPN cells to secrete significant amounts of OPN.
Transfection with OPN gene result in increased multidrug resistance The IC 50 of NVB against OPN7 cells and OPN8 cells were 3.87 ± 0.47 ng/ml and 4.56 ± 0.89 ng/ml, respectively, whereas those against Neo1 cells, Neo2 cells and parental cells were 1.70 ± 0.04 ng/ml, 1.97 ± 0.71 ng/ ml and 1.91 ± 0.11 ng/ml, respectively (Figure 1b) . The IC 50 of VP16 against OPN7 cells and OPN8 cells were 8.71±0.34 mM and 15.76±1.49 mM, respectively, whereas those against Neo1 cells, Neo2 cells and parental cells were 4.47 ± 1.51 mM, 3.69 ± 1.00 mM and 2.17 ± 0.19 mM, respectively ( Figure 1c ). As IC 50 never reached at any concentration of GEM in OPN transfectants, we could not show the IC 50 regarding OPN transfectants. The IC 50 of GEM against Neo1 cells, Neo2 cells and parental cells were 0.05 ± 0.002 mM, 0.03 ± 0.02 mM and 0.04 ± 0.018 mM, respectively (Figure 1d ). The IC 50 of CDDP against OPN7 cells and OPN8 cells were 6.44 ± 0.18 mg/ml and 5.85 ± 0.40 mg/ml, respectively, whereas those against Neo1 cells, Neo2 cells and parental cells were 12.00±1.52 mg/ml, 11.56±2.68 mg/ ml and 3.39±1.68 mg/ml, respectively (Figure 1e ). These results indicate that the ACC-MESO-1/OPN cells were more resistant to NVB, VP-16 and GEM than the ACC-MESO-1/Neo or parental cells, whereas ACC-MESO-1/ OPN cells did not demonstrate resistance to CDDP. We next evaluated the amount of apoptotic cells (Figure 1f ). We observed that ACC-MESO-1/OPN cells were more significantly resistant to apoptosis mediated by anticancer agents than ACC-MESO-1/Neo cells. These data indicate that the transfection with OPN gene thus resulted in an increased multidrug resistance. Moreover, transfection with OPN gene also increased resistance to apoptosis induced by NVB, VP-16 and GEM.
OPN regulates cell adhesion to HA To evaluate the effect of OPN transfected to ACC-MESO-1 cells on OPN or HA binding, an in vitro cell adhesion assay was performed using ACC-MESO-1/ OPN, ACC-MESO-1/Neo and parental cells. The cells were investigated for adhesion to OPN, HA or BSA (Figure 2a) . Interestingly, the ratio of adherence to HA (percent-specific adhesion to HA/percent-specific adhesion to BSA) of ACC-MESO-1/OPN cells was significantly greater than that of the ACC-MESO-1/Neo and parental cells, whereas neither ACC-MESO-1/OPN cells nor ACC-MESO-1/Neo cells demonstrated adherence to OPN (Table 1) . To investigate whether the silencing of the OPN expression abrogates enhanced adhesion to HA, we downregulated the OPN expression in ACC-MESO-1/OPN#8 cells by siRNA. siRNA transfection downregulated the OPN expression by 480% (Figure 2b ) and then we next performed an adhesion assay. As expected, the silencing of OPN expression in ACC-MESO-1/OPN#8 cells decreased the adhesion to HA (Figure 2c ). These results therefore suggest that OPN regulates the cell adhesion to HA.
Expression of CD44 and CD44 variant isoforms
As ACC-MESO-1/OPN cells showed an enhanced adhesion to HA, we therefore compared the expression levels of CD44, a principle receptor for HA, on the surface of ACC-MESO-1/OPN, ACC-MESO-1/Neo and parental cells with FACScan. As shown in Figure 3a , there was no difference in the total CD44 surface expression among ACC-MESO-1/OPN, ACC-MESO-1/Neo and parental cells. As certain CD44 variant isoforms have been reported to display significantly less HA binding than CD44s (Iida and Bourguignon, 1997) , we next examined the expression pattern Osteopontin induces drug resistance in mesothelioma cells K Tajima et al of the CD44 variant isoforms using RT-PCR ( Figure 3b ) and western blotting ( Figure 3c ). It was noteworthy that the fragment of CD44s, which was expected to exhibit a PCR amplification product of 375 bp and several other larger fragments were expressed in each clone, thus suggesting the presence of alternatively spliced transcripts (Figure 3b ). To identify these larger fragments, a direct DNA sequence analysis was performed. The 550 bp product corresponds to exon14 (v10), whereas the 750 bp product corresponds to exons12, 13 and 14 (v8, v9 and v10, respectively) (data not shown). CD44 protein expression was analyzed by western blotting using BU52. The expression of high molecular weight CD44 variant isoforms was significantly decreased in the ACC-MESO-1/OPN cells in comparison compared to that of the ACC-MESO-1/Neo and parental cells (Figure 3c ). To determine whether exogenous OPN regulates the expression of CD44 variant isoforms on ACC-MESO-1 cells, a western blot analysis was performed to evaluate the CD44 isoform expression on the ACC-MESO-1 cells cultured on OPN and BSA. The expression of high molecular weight CD44 variant isoforms significantly decreased in the ACC-MESO-1 cells cultured on OPN compared with that of the ACC-MESO-1 cells cultured on BSA (Figure 3d ).
Downregulation of CD44v10 expression increases the multidrug resistance
To investigate whether the downregulation of the CD44v10 expression is involved in the mechanism of the multidrug resistance, we downregulated the CD44v10 expression in ACC-MESO-1 cells by siRNA. siRNA transfection downregulated the CD44v10 expression by 480% and then a chemosensitivity assay was performed (Figure 4a ). The IC 50 of NVB against the ACC-MESO-1 cells transfected with CD44v10 siRNA was 17.47 ± 7.00 ng/ml, whereas those against the cells transfected with control siRNA was 2.54 ± 0.31 ng/ml ( Figure 4b ). The IC 50 of NVB against the ACC-MESO-1 cells transfected with CD44v10 siRNA was significantly higher than that against the cells transfected with control siRNA (Po0.05). The IC 50 of VP16 against the ACC-MESO-1 cells transfected with CD44v10 siRNA was 10.53 ± 0.11 mM, whereas those against the cells transfected with control siRNA was 2.36±0.20 mM (Figure 4c ). The IC 50 of VP-16 against the ACC-MESO-1 cells transfected with CD44v10 siRNA was significantly higher than that against the cells transfected with control siRNA (Po0.05). As IC 50 was never (Figure 4d ). As expected, the silencing of the CD44v10 expression in ACC-MESO-1 cells increases the multidrug resistance. The silencing of CD44v10 expression in ACC-MESO-1 cells also increases adhesion to HA (data not shown). These results suggest that the downregulation of CD44v10, accompanied by the enhanced adhesion to HA, is involved in the multidrug resistance.
Inhibition of the HA-CD44 interaction abrogated multidrug resistance and resistance to apoptosis To determine whether HA-CD44 interaction is involved in the mechanism of the multidrug resistance, the expression of CD44 in ACC-MESO-1/OPN and ACC-MESO-1/Neo cells were downregulated by siRNA. siRNA transfection downregulated the CD44 expression by 470% and then a chemosensitivity assay was performed ( Figure 5a ). The IC 50 of NVB against the OPN8 cells transfected with CD44 siRNA, OPN8 cells transfected with control siRNA, Neo2 cells transfected with CD44 siRNA and Neo2 cells transfected with control siRNA were 1.10±0.11 ng/ml, 5.33±0.49 ng/ml, 1.65±0.13 ng/ml and 1.61±0.20 ng/ml, respectively (Figure 5b (Figure 5d ). As expected, the silencing of the CD44 expression in ACC-MESO-1/ OPN#8 cells abrogated the multidrug resistance and increased apoptotic cells in number (Figure 5e ). In contrast, silencing of CD44 expression did not influence the chemosensitivity in ACC-MESO-1/Neo#2 cells. ACC-MESO-1/OPN cells in the absence or the presence of BU75 were also cultured with VNB, VP-16 and GEM. As shown in Figure 5f , inhibition of the HA-CD44 interaction increased apoptosis and abrogated resistance to apoptosis. To confirm that the resistance to apoptosis was mediated by overexpression of OPN, we downregulated OPN expression by siRNA and performed the same experiment (Figure 5g ). We again observed the downregulation of OPN expression to increase apoptosis. These results together with Figure 3c suggest that OPN-mediated alteration in HA-CD44 binding is involved in the mechanism of multidrug Osteopontin induces drug resistance in mesothelioma cells K Tajima et al resistance and resistance to apoptosis induced by NVB, VP-16 and GEM.
CD44-mediated resistance to apoptosis involves the Akt survival pathway
As the Akt pathway is a well-characterized kinase that promotes cellular survival and several researchers have already shown that HA activates the PI3k-Akt signaling pathway (Sohara et al., 2001; Ghatak et al., 2002; Zoltan-Jones et al., 2003) , we therefore investigated whether the survival signal emanating from the HA-CD44 interaction is mediated by the activation of the Akt pathway. To assess Akt phosphorylation, immunoblotting with anti-Akt and phospho-Akt-specific antibodies was carried out in ACC-MESO-1/OPN and ACC-MESO-1/Neo cells ( Figure 6a ). As expected, the enhanced level of phosphorylation of Akt (p-Akt) was observed in the ACC-MESO-1/OPN cells. To investigate whether the HA-CD44 interaction mediates p-Akt, the CD44 expression was thus downregulated by siRNA and then the p-Akt expression was assessed. As shown in Figure 6b , the elevation of p-Akt in the ACC-MESO-1/OPN cells decreased by the downregulation of CD44. To substantiate the functional role of Akt activation in the resistance to apoptosis, Akt inhibitor (LY294002) was used to block Akt activation.
ACC-MESO-1/OPN cells with or without LY294002
were cultured in the presence of VNB, VP-16 and GEM and apoptosis was detected by Annexin V (Figure 6c ). As expected, the inhibition of the Akt phosphorylation increased the number of cells that underwent apoptosis. These results suggest that the activation of the Akt survival pathway, induced through the CD44, is therefore involved in the resistance to apoptosis induced by NVB, VP-16 and GEM.
Discussion
We here demonstrated that OPN provides MPM cells with an increased multidrug resistance and resistance to apoptosis to anti-cancer agents through HA-CD44 interaction. OPN-mediated alteration in CD44 binding to HA appears to have an important role in obtaining multidrug resistance by ACC-MESO-1/OPN cells. In this study, the transfection of the OPN gene mediated the upregulation of HA binding in MPM cells. In contrast, the silencing of the OPN gene in ACC-MESO-1/OPN cells abrogated an enhanced adhesion to HA. These results indicate that OPN either directly or indirectly regulates HA binding. How does OPN gene transfer confer enhanced HA binding? First of all, we quantified and compared the amount of HA secreted into medium by both OPN transfectants. As opposed to our hypothesis, there was no difference in the amount of secreted HA (data not shown). In contrast, the expression of high molecular weight CD44 variant isoforms containing v8-10 and v10 was significantly reduced in ACC-MESO-1/OPN cells in comparison with control transfectants, whereas total CD44 expression levels on both transfectants are equivalent. As Iida and Bourguignon, (1997) demonstrated that cells coexpressing both transfected CD44v10 and endogeneous CD44s display a significant reduction in HA-mediated cell adhesion in comparison with parental cells expressing only CD44s, OPN-mediated enhanced HA binding in this study appears to be attributable to the downregulation of the CD44 variant isoforms, but not to the upregulation of CD44 expression.
Recent studies have revealed that HA strongly promotes anchorage-independent growth and that the resistance of cancer cells to growth arrest and apoptosis under anchorage-independent conditions is dependent on the constitutive interactions between HA and CD44 (Li and Heldin, 2001; Zoltan-Jones et al., 2003) . The treatment of tumor cells with hyaluronidase was observed to increase the activities of various chemotherapeutic agents. In contrast, an increased HA production has been reported to induce resistance in drug-sensitive tumors (Misra et al., 2003) . In our study, ACC-MESO-1/OPN cells which showed an enhanced adhesion to HA obtained multidrug resistance, and a disruption of HA-CD44 interaction by siRNA or neutralizing anti-CD44 antibody abrogated the resistance to apoptosis. Several groups have revealed that HA activates the PI3K-Akt signaling pathway through CD44, thereby promoting cell survival (Sohara et al., 2001; Ghatak et al., 2002; Zoltan-Jones et al., 2003) . In fact, hyaluronan oligomers (oHA), which compete for endogenous polymeric HA, suppresses the PI3K/Akt cell survival pathway and retains chemosensitivity to anti-cancer agents (Cordo Russo et al., 2008) . In our study, the downregulation of the CD44 expression by siRNA suppressed Akt phosphorylation and increased apoptotic cells in number by the treatment with anticancer agents. These results suggested that OPNinduced resistance to apoptosis in the mesothelioma is mediated by the PI3K/Akt signaling pathway. Khan et al. (2005) demonstrated that OPN upregulates the CD44v6, nine expressions, which have a key role in cancer metastasis, and the upregulation of variant CD44 isoforms has been reported to facilitate breast cancer cell migration . In contrast, OPN gene transfer in MPM cells reduced the CD44v8-10, ten expressions, and the downregulation of these variant CD44 isoforms confers chemoresistance of MPM in this study. The difference in OPN-induced alteration of CD44 isoforms may reflect the difference in the cell type between breast cancer and MPM. In MPM, local invasiveness is characteristic, whereas distant metastasis is infrequently observed. Such invasive growth requires ECM for MPM cells as previously reported (Li and Heldin, 2001) . Moreover, the acquisition of chemoresistance by HA-CD44 interaction could be advantage for MPM cells to protect themselves by anti-cancer agents. These ideas are supported by previous reports which demonstrated MPM to be associated with elevated levels of OPN and HA in the pleural effusion (Thylen et al., 1997; Pass et al., 2005; Grigoriu et al., 2007) .
In this study, ACC-MESO-1/OPN cells, which showed an enhanced HA binding were shown to be more resistant to anti-cancer agents, NVB, VP-16 and GEM. These agents confer antitumor ability by a different mechanism. NVB binds to tubulin and inhibits its polymerization to form microtubules. VP-16 acts through inhibition of DNA topoisomerase II. GEM requires intracellular activation to its triphosphate derivative dFdCTP, which incorporates into DNA and then inhibits DNA synthesis. However, whether resistance to these three agents is mediated by the same mechanism still remains to be elucidated. We found the inhibition of the Akt phosphorylation by LY294002 to increase the number of cells that underwent apoptosis by the treatment with all three agents. These results suggested that the activation of the Akt survival pathway, induced through the CD44, may therefore be involved in the resistance to these three agents. Although, there still remains the question of what downstream events of the Akt pathway are involved in multidrug resistance, the inhibition of HA-CD44 or Akt pathway in combination with conventional agents may be more useful than conventional chemotherapy in the treatment of MPM.
To confirm that these findings can be generalized, we also examined other mesothelioma cell lines, such as H28 and ACC-MESO-4. Unfortunately, all mesothelioma cell lines tested, except ACC-MESO-1, expressed significant mRNA amounts of OPN by RT-PCR (data not shown). We therefore tried to downregulate the OPN expression in H28, which secreted significant amounts of OPN, by siRNA or miRNA to evaluate the role of OPN in chemoresistance. However, we were unable to establish stable transfectant by miRNA. siRNA transfection also could not downregulate the OPN expression. Although our data, in which OPN is involved in the chemoresistance, is promising, we still need to confirm that these results can be generalized by using animal models in the future.
In summary, we herein demonstrated that OPN mediated the alteration in HA-CD44 binding and that HA-CD44 interaction therefore has an important role in the acquisition of multidrug resistance by MPM. These results highlight the potential importance of OPN, which modulates HA-CD44 interaction, as a therapeutic target in multidrug resistance in patients with MPM.
Materials and methods

Cell lines
The human mesothelioma cell lines, ACC-MESO-1 cells were established at the Aich Cancer Center Research Institute (Nagoya, Japan) (Usami et al., 2006) . The cells were maintained in RPMI-1640 (Kohjin Bio, Sakado-city, Saitama Japan) containing 10% fetal calf serum (FCS), penicillin (100 U/ml) and streptomycin (100 mg/ml) at 37 1C in 5% CO 2 atmosphere. The cells were routinely tested for Mycoplasma contamination using the MycoAlert Mycoplasma Detection Kit (Cambrex, Rockland, ME, USA).
Reagents
The monoclonal anti-CD44 antibody (BU52), which is directed against epitopes common to all CD44 isoforms and the monoclonal anti-CD44 antibody (BU75), which blocks hyaluronate (HA) binding to CD44, were purchased from Ancell Corp (Bayport, MN, USA). The rabbit anti-Osteopontin (OPN) polyclonal antibody was purchased from Immuno-Biological and Laboratories (Gunma, Japan). The rabbit anti-Akt polyclonal antibody and the rabbit antiphospho-Akt antibody were purchased from Cell Signaling Technology (Beverly, MA, USA). LY294002 was purchased from Sigma Chemicals (St Louis, MO, USA). To evaluate cell viability, the Cell Counting Kit-8 was purchased from Wako (Osaka, Japan).
Transfection
We have previously described the eukaryotic cDNA expression vector BMG Neo, conferring neomycin resistance, and BMGNeo containing the murine OPN cDNA was designated as BMGNeo-OPN (Takahashi et al., 2002) . BMGNeo and BMGNeo-OPN were transfected into ACC-MESO-1 cells using Lipofectamine 2000 Reagent (Invitrogen Corporation, Camarillo, CA, USA) according to the manufacture's instructions. The cells were selected with medium containing 0.5 mg/ ml of 418 sulfate (Geneticin; Invitrogen Corporation). Several clones were isolated with limiting dilution. The resulting selected and isolated cells transfected with BMGNeo-OPN and BMGNeo were designated as ACC-MESO-1/OPN and ACC-MESO-1/Neo, respectively.
Detection of CD44 transcription by reverse transcriptasepolymerase chain reaction
The expression of CD44 mRNA was assessed by RT-PCR. TaKaRa FastPure RNA kit (Takara, Japan) was used to extract RNA according to the manufacturer. cDNA was synthesized using SuperscriptIII reverse transcriptase (Invitrogen Corporation). To detect CD44 variant isoform expression, the sense primer; 5 0 -GACAAGTTTTGGTGGCACGCA-3 0 , and antisense primer; 5 0 -TCAGATCCATGAGTGGTATGGG AC-3 0 were used. This amplifies the intervening region of the transcripts including any inserted exons of the variant (CD44v) region. Amplifications for b-actin (sense primer, 5 0 -AGAAA ATCTGGCACCACACC-3 0 ; antisense primer, 5 0 -AGGAGG GAAGGCTGGAAGAG-3 0 ) were performed in TaKaRaExTaq polymerase (Takara, Japan). The PCR conditions were 2 min at 95 1C; 25 cycles of 1 min at 95 1C, 1 min at 55 1C, and 1 min at 72 1C, followed by a 7-min incubation at 72 1C.
Sequence RT-PCR was performed under the same conditions as described above. The PCR products were purified by using MinElute (Qiagen, Maryland, MD, USA). Sequencing was performed using commercial reagents and an automated sequencer (ABI Prism BigDye Terminator v1.1 Cycle Sequencing Kit and ABI 3130 Genetic Analyzer; both Applied Biosystems, Foster city, CA, USA).
Detection of OPN protein secretion by ELISA
To determine OPN secretion in culture supernatant, a commercial ELISA kit (Immuno-Biological and Laboratories) was used according to the manufacture's instructions. Briefly, ACC-MESO-1/OPN and ACC-MESO-1/Neo were plated at 5 Â 10 5 cells/well in 6-well 35 mm culture plates in 3 ml medium with 10% FCS. After 24 h, the culture medium was replaced with a medium containing 1% FCS for an additional 48 h. The culture supernatants were collected and subjected to an ELISA analysis.
In vitro chemosensitivity assay The ells (2.0 Â 10 3 ) were seeded onto 96-well microtiter plates in the absence or the presence of various concentration of chemotherapeutic agents including vinorelbine (VNB, Kyowa Hakko, Tokyo, Japan), etoposide (VP-16, Sigma), gemcitabine (GEM, Eli Lilly, Kobe, Japan) and cisplatin (CDDP, LKT Laboratories, St Paul, MN, USA). After 72 h of incubation, 10 ml of Cell Counting Kit-8 was added to each well. Four hours later, the optical density was measured at 450 nm with a microplate reader (Bio-Rad, Richmond, CA, USA). The results are expressed as the percentage of cell viability.
Adhesion assay
Ninety-six-well flat bottom plates (Corning Incorporated, Corning, New York, USA) were coated with recombinant OPN (1 and 5 mg/ml) or HA (0.01, 0.1 and 1 mg/ml) or 10 mg/ ml BSA in PBS overnight at 4 1C. The following procedures were previously described (Takahashi et al., 2003) .
RNA interference assay ACC-MESO-1/OPN cells were transfected with 5 nM OPN siRNA using Hiperfect Transfection Reagent (Qiagen) or 10 nM CD44 and CD44v10 siRNA using Lipofectamine RNAiMAX (Invitrogen Corporation) according to the manufacturer's instructions. A knockdown efficacy was evaluated by Western bloting. Small interfering RNAs directed against OPN (spp1) (Mm_Spp1_1_HP siRNA), CD44 (5 0 -AAAUGG UCGCUACAGCAUCTT-3 0 ), CD44v10 (5 0 -CACACGAAGG AAAGCAGGACCUUCA-3 0 ) and a negative control (Allstars Negative Control siRNA) were purchased from either Qiagen or Invitrogen. The ACC-MESO-1/OPN cells transfected with siRNA for OPN, CD44 and negative control siRNA were designated as ACC-MESO-1/OPN OPN siRNA, ACC-MESO-1/OPN CD44 siRNA and ACC-MESO-1/OPN control siRNA, respectively.
Western bloting
For the Western blot analyses, the cells were homogenized in lysis buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 0.02% NaN3, 1 mM phenylmethylsulfonylfluoride, 1 mg/ml aprotinin, 1% Triton-X-100). Samples containing equal amounts of protein were separated on acrylamide gels and transferred to a nitrocellulose filter with electroblotting. The filters were blocked for 1 h in PBS containing 0.1% Tween-20 (PBS-T) and 5% dry milk, washed in PBS-T, and then incubated with BU52 (1:500), rabbit anti-Osteopontin polyclonal antibody (1:500), rabbit anti-Akt polyclonal antibody (1:1000), rabbit anti-phospho-Akt antibody (1:1000) and monoclonal anti-bactin antibody (1:4000) at 4 1C overnight. The filters were again washed and then incubated with horseradish-peroxidaseconjugated anti-mouse IgG or anti-rabbit IgG antibody (Amersham Pharmacia Biotech, Buckinghamshire, UK) for 1 h. Filters were then washed in PBS-T, and specific proteins were detected using the enhanced chemiluminescence system (Amersham Pharmacia Biotech).
Flowcytometric analysis
The adherent cells were detached from plates with 0.05% EDTA in PBS and were washed in PBS containing 0.1% BSA. Then, the cells (5 Â 10 5 ) were incubated with BU52 (1 mg/ml) in PBS containing 0.1% BSA at 4 1C for 30 min. After washing the cells, the cells were incubated with fluorescent-labeled antimouse IgG (Chemicon, Temecula, CA, USA). The Propidium Iodide (Sigma) was added to final concentration of 10 mg/ml to exclude dead cells. Fluorescence was analyzed with a FACScan (Becton-Dickson Co., Mountain view, CA, USA).
Evaluation of apoptosis by Annexin V ACC-MESO-1/OPN cells transfected with CD44 siRNA, OPN siRNA and negative control cells were treated with VNB, VP-16, or GEM for 48 h in the presence or absence of LY294002. Cells were harvested and the Annexin V-FITC -PI Kit (Sigma Inc.) was used according to the manufacturer's instructions. Earlystage apoptotic cells were Annexin positive and PI negative (right lower quadrant) and late-stage apoptotic cells were labeled by positivity with Annexin V and PI (right upper quadrant). The percentage of apoptotic cells was assessed by adding the percentage of cells in the two right quadrants.
Statistics
A statistical analysis was performed with an analysis of variance (ANOVA). The differences between the means were considered to be statistically significant at Po0.05.
